CAN FITE BIOPHARMA LTD-ADR (CANF)
US13471N3008 - ADR
CANF gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of CANF is average, but there are quite some concerns on its profitability. CANF is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CANF had negative earnings in the past year.
CANF had a negative operating cash flow in the past year.
CANF had negative earnings in each of the past 5 years.
CANF had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CANF's Return On Assets of -76.42% is on the low side compared to the rest of the industry. CANF is outperformed by 69.52% of its industry peers.
Looking at the Return On Equity, with a value of -122.28%, CANF is in line with its industry, outperforming 40.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.42% | ||
| ROE | -122.28% | ||
| ROIC | N/A |
ROA(3y)-87.03%
ROA(5y)-114.94%
ROE(3y)-151.83%
ROE(5y)-244.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CANF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
CANF has more shares outstanding than it did 1 year ago.
CANF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CANF has an Altman-Z score of -22.35. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
CANF has a Altman-Z score of -22.35. This is amonst the worse of the industry: CANF underperforms 87.33% of its industry peers.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.35 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
CANF has a Current Ratio of 4.90. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF has a Current ratio of 4.90. This is comparable to the rest of the industry: CANF outperforms 53.25% of its industry peers.
CANF has a Quick Ratio of 4.90. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF's Quick ratio of 4.90 is in line compared to the rest of the industry. CANF outperforms 53.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.54% over the past year.
CANF shows a decrease in Revenue. In the last year, the revenue decreased by -8.27%.
CANF shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.92% yearly.
EPS 1Y (TTM)50.54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q69.1%
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y-27.92%
Revenue growth Q2Q-21.32%
3.2 Future
CANF is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.38% yearly.
The Revenue is expected to grow by 97.60% on average over the next years. This is a very strong growth
EPS Next Y15.09%
EPS Next 2Y9.76%
EPS Next 3Y6.38%
EPS Next 5YN/A
Revenue Next Year433.92%
Revenue Next 2Y91%
Revenue Next 3Y97.6%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CANF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CANF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.76%
EPS Next 3Y6.38%
5. Dividend
5.1 Amount
No dividends for CANF!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CAN FITE BIOPHARMA LTD-ADR
NYSEARCA:CANF (4/25/2024, 11:05:32 AM)
1.97
+0.03 (+1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.83M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.42% | ||
| ROE | -122.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.9 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50.54%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y15.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y